Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction
<p>Abstract</p> <p>Currently the world faces epidemic of several closely related conditions: obesity, metabolic syndrome and type 2 diabetes (T2DM). The lipid profile of these patients and those with metabolic syndrome is characterized by the concurrent presence of qualitative as w...
Main Authors: | Tenenbaum Alexander, Fisman Enrique Z |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2012-10-01
|
Series: | Cardiovascular Diabetology |
Subjects: | |
Online Access: | http://www.cardiab.com/content/11/1/125 |
Similar Items
-
Anti-atherogenic effects of fibrates in type 2 diabetes
by: Barter Philip
Published: (2001-09-01) -
Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?
by: Tenenbaum Alexander, et al.
Published: (2012-11-01) -
Which is the best lipid-modifying strategy in metabolic syndrome and diabetes: fibrates, statins or both?
by: Tenenbaum Alexander, et al.
Published: (2004-12-01) -
Combined statin-fibrate therapy-induced rhabdomyolysis: Case report
by: Jozić Tanja L., et al.
Published: (2014-01-01) -
Efficacy of Pemafibrate in Comparison to Fenofibrate and Bezafibrate on Triglyceride Levels and Liver, and Renal Functions in Patients With Hypertriglyceridemia and Type 2 Diabetes
by: Junko Oya, et al.
Published: (2023-11-01)